EUDA Health Launches New iPSC-Derived Skin Stem Cell Mask, Expanding Helixé Line
EUDA has more than doubled off its 52-week low of $5.26.
Summary
EUDA Health launched its new Regenixé iPSC-derived Skin Stem Cell Secretome Mask, expanding its Helixé product line for which it holds exclusive global distributorship rights. This product aims to tap into the growing global face mask market, estimated at nearly $8 billion in 2026, leveraging EUDA's distribution networks in Asia-Pacific. The launch follows recent news of the company regaining Nasdaq compliance, indicating an effort to build out its product offerings amidst prior financial and compliance challenges.
At the time of this announcement, EUDA was trading at $18.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45M. The 52-week trading range was $5.26 to $86.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.